Journal Article

FZJ-2021-03023

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1G93A Transgenic Mice

Post, J.FZJ* ; Schaffrath, A.FZJ* ; Gering, I.FZJ* ; Hartwig, S. ; Lehr, S. ; Shah, N. J.FZJ* ; Langen, K.-J.FZJ* ; Willbold, D.FZJ* ; Kutzsche, J.FZJ* ; Willuweit, A. (Corresponding author)FZJ*

2021
Molecular Diversity Preservation International Basel

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/28208  doi:10.3390/ijms22137066

Abstract: Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and plays a key role in the pathogenesis of amyotrophic lateral sclerosis (ALS). It has been implicated as driver of disease progression and is observed in ALS patients, as well as in the transgenic SOD1G93A mouse model. Here, we explore and validate the therapeutic potential of the d-enantiomeric peptide RD2RD2 upon oral administration in SOD1G93A mice. Transgenic mice were treated daily with RD2RD2 or placebo for 10 weeks and phenotype progression was followed with several behavioural tests. At the end of the study, plasma cytokine levels and glia cell markers in brain and spinal cord were analysed. Treatment resulted in a significantly increased performance in behavioural and motor coordination tests and a decelerated neurodegenerative phenotype in RD2RD2-treated SOD1G93A mice. Additionally, we observed retardation of the average disease onset. Treatment of SOD1G93A mice led to significant reduction in glial cell activation and a rescue of neurons. Analysis of plasma revealed normalisation of several cytokines in samples of RD2RD2-treated SOD1G93A mice towards the levels of non-transgenic mice. In conclusion, these findings qualify RD2RD2 to be considered for further development and testing towards a disease modifying ALS treatment.

---

Contributing Institute(s):

1. Physik der Medizinischen Bildgebung (INM-4)
2. Jara-Institut Quantum Information (INM-11)
3. Jülich-Aachen Research Alliance - Translational Brain Medicine (JARA-BRAIN)
4. Strukturbiochemie (IBI-7)

Research Program(s):

1. 354 - Disease Prevention and Healthy Aging (POF4-354) (POF4-354)
2. 5244 - Information Processing in Neuronal Networks (POF4-524) (POF4-524)

Appears in the scientific report 2021

---

Database coverage:
; ; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---